Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Abstract: Molecules having potential biological activity, particularly peptoids, that are conjugated to solid phase supports, spacer groups, and/or ligation moieties, and methods of their preparation, are described. In some instances, the molecules of the invention are made entirely by solid phase synthesis. In other instances, the spacer groups are hydrophilic and compositions containing them, and to solid phase synthesis of varied structure peptoids using chemoselective ligation moieties.
Abstract: Pharmaceutical foam compositions substantially free of ethanol and comprising pimecrolimus in a carrier vehicle comprising a mixture of oily solvents amounting to at least 40% of the total weight of the composition and consisting of: i) hexylene glycol; ii) optionally oleyl alcohol; and iii) dimethylisosorbide and/or medium chain triglycerides; and additionally: iv) when oleyl alcohol is absent, water in an amount of less than 25%; v) at least one consistency agent; vi) at least one preservative; and vii) at least one surfactant/emulgator; and propellant gas for foaming; and optionally further conventional excipients. They are indicated for use in the treatment of various skin, nail and mucosal diseases.
Type:
Application
Filed:
April 7, 2005
Publication date:
July 31, 2008
Applicant:
NOVARTIS AG
Inventors:
Meir Eini, Doron Friedman, Stefan Hirsch, Sabine Meyenburg, Nabila Sekkat, Dov Tamarkin
Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
Type:
Application
Filed:
March 3, 2008
Publication date:
July 31, 2008
Applicant:
Novartis Vaccines and Diagonstics, Inc.
Inventors:
Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
Abstract: The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial, a low toxicity, low coefficient of friction, and increased hydrophilicity while maintaining the desired bulk properties such as oxygen permeability and ion permeability of lens material. Such lenses are useful as extended-wear contact lenses. In addition, the invention provides a method for making a medical device, preferably a contact lens, having an antimicrobial coating thereon.
Type:
Grant
Filed:
November 4, 2002
Date of Patent:
July 22, 2008
Assignee:
Novartis AG
Inventors:
Carol Ann Morris, Manal M. Gabriel, Yongxing Qiu, Lynn Cook Winterton, John Martin Lally, Marcia Kay Ash, Fiona Patricia Carney, Courtney Flem Morgan
Abstract: The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
Type:
Grant
Filed:
November 5, 2002
Date of Patent:
July 22, 2008
Assignee:
Novartis AG
Inventors:
Ying-Nan Pan Chen, Peter Lassota, Alexander Wallace Wood
Abstract: A method for inducing differentiation of embryonic stem cells into neuronal precursors is provided as well as an assay for neuronal precursor or progenitor cells and a method for identifying agents that inhibit or reduce an increase in neurite degeneration.
Type:
Application
Filed:
May 4, 2005
Publication date:
July 17, 2008
Applicant:
NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITU FOR BIOMEDICAL RESEARCH
Inventors:
Yves-Alain Barde, Miriam Bibel, Jens Richter, Kerry Lee Tucker
Abstract: The invention relates to new phthalazine derivatives of formula (I), wherein R1 and R2: a) are independently in each case a lower alkyl; b) together form a bridge of subformula (I*), wherein the bond is achieved via the two terminal C atoms and m is 0 to 4; or c) together form a bridge of subformula (I**), wherein one or two of the ring members T1, T2, T3 and T4 are nitrogen, and the others are in each case CH, and the bond is achieved via atoms T1 and T4; A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N; X is imino, oxa, or thia; Y is hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or unsubstituted or substituted cycloalkyl; and wherein the bonds characterized in subformula (I*) by a wavy line are either single or double bonds; to an N-oxide of a compound of formula I; a tautomer or mixture of tautomers of a compound of formula (I) of an N-oxide thereof; and a pharmaceutically acceptable s
Abstract: The present invention relates to novel benzo [g] quinoline derivatives, their preparation, their use as pharmaceuticals for use in the treatment of glaucoma and myopia.
Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
Type:
Grant
Filed:
April 9, 2004
Date of Patent:
July 15, 2008
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
Abstract: The present invention provides for a method for identifying an agent that has an inhibitory effect on the complex-formation of an ARE-containing mRNA and an HuR protein.
Abstract: Disclosed are compounds of formula I: wherein R1, R2, R3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.
Type:
Grant
Filed:
October 6, 2003
Date of Patent:
July 15, 2008
Assignee:
Novartis AG
Inventors:
Rainer Albert, Nigel Graham Cooke, Gebhard Thoma, Christian Bruns, François Nuninger, Markus Streiff, Hans-Günter Zerwes
Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 10, 2008
Applicants:
IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AG
Inventors:
Valentina Molteni, Xiaolin Li, Donatella Chianelli, Juliet Nabakka, Jon Loren, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.
Type:
Grant
Filed:
June 7, 2001
Date of Patent:
July 8, 2008
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.
Type:
Grant
Filed:
March 20, 2006
Date of Patent:
July 8, 2008
Assignees:
IRM LLC, Novartis AG
Inventors:
Stuart Bevan, Pamposh Ganju, Peter McIntyre, Ardem Patapoutian, Andrea Peier, Chuanzheng Song
Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.
Type:
Application
Filed:
January 3, 2008
Publication date:
July 3, 2008
Applicant:
Novartis Vaccines and Diagnostics, s.r.l.
Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
July 1, 2008
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
Abstract: The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.